Today: 7 February 2026
Subscribe

SoFi Stock Soars 171% to Record Highs on Breakout Earnings – Will the Rally Continue? (Nov 2025 Update)

SoFi Stock Soars 171% to Record Highs on Breakout Earnings – Will the Rally Continue? (Nov 2025 Update)

Stock Price & Recent Performance (Nov 2025) SoFi Technologies’ stock has been on a tear in 2025, dramatically outperforming the broader market. As of November 5, 2025, SOFI trades around $29–30 per share, not far from its all-time high set just days earliertradingview.com. In late October, the stock spiked to an intraday record of $32.57 (an all-time high)247wallst.com, buoyed by optimism around its earnings. Even after pulling back about 7% from the peak in early November247wallst.com, SoFi shares are still up roughly 91% year-to-date and +171% versus a year agotradingview.com – a meteoric rise that has put the fintech firmly
5 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20sreuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billionstockanalysis.com – substantially smaller than several years ago and dwarfed
5 November 2025
····
Cipher Mining Stock Skyrockets on Blockbuster AWS Deal – Latest Earnings, Expert Insights & Price Forecast

Cipher Mining Stock Skyrockets on Blockbuster AWS Deal – Latest Earnings, Expert Insights & Price Forecast

Stock Performance and Recent Trends (Past Week) Cipher Mining’s stock has been on a tear. In the final week of October into early November 2025, CIFR rocketed from the high teens to the mid-$20s per sharestockanalysis.comstockanalysis.com. On Monday, Nov 3, shares opened slightly down but closed up over 22% in a single session247wallst.com – an eye-popping move for a mid-cap stock. This surge was directly catalyzed by the company’s Q3 earnings release and strategic partnership news (more on that below). By mid-day Nov 5, CIFR was trading around $25 (+11% intraday)stockanalysis.com, marking roughly a 35% gain week-to-date and a new
5 November 2025
····
Rubico (RUBI) Stock in Freefall: Top Ships Spin-Off Collapses 90% – What Investors Should Know

Rubico (RUBI) Stock in Freefall: Top Ships Spin-Off Collapses 90% – What Investors Should Know

Company Overview: Business Model & Background Rubico Inc. is a Marshall Islands-incorporated shipping company providing crude oil transportation services via a small fleet of tankersglobenewswire.comglobenewswire.com. The company was created as a spin-off from TOP Ships Inc., a Greek tanker owner, to separately house two Suezmax oil tankers (M/T Eco Malibu and M/T Eco West Coast)stocktwits.com. Both 2021-built vessels are “eco” fuel-efficient tankers on long-term time charter contracts with Clearlake (a major commodity trading firm), ensuring stable charter revenue streamsrivieramm.com. Rubico’s strategy focuses on owning and operating these modern tankers, leveraging their high specification and scrubber-fitted fuel efficiency to attract charterersglobenewswire.com.
5 November 2025
····
First Majestic Silver (AG) Shines on Silver’s Surge – But Can the Rally Sustain?

First Majestic Silver (AG) Shines on Silver’s Surge – But Can the Rally Sustain?

Stock Performance and Technical Trends First Majestic’s stock has had a rollercoaster year, skyrocketing through 2025 alongside the price of silver. The share price climbed from the ~$5 level in January to a 52-week high of $15.69 by late Octoberreuters.com, vastly outperforming broader mining indices. This 158% year-to-date surge was propelled by optimism around the Los Gatos acquisition and leverage to silver’s historic rallyinvesting.com. Recent weeks have seen some consolidation. After the Q3 earnings miss in early November, AG pulled back roughly 20–30% from its peak, dipping into the low $10sreuters.com. Technical indicators reflect this cooling momentum: the stock broke
5 November 2025
····
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a
5 November 2025
····
Lumentum Stock Skyrockets on AI Boom – Record Sales & Bold Forecast

Lumentum Stock Skyrockets on AI Boom – Record Sales & Bold Forecast

Recent News: Earnings Spark Rally Lumentum’s San Jose headquarters. The company’s stock jumped after it announced record quarterly revenue and upbeat guidance, fueled by surging demand from AI data centers. Lumentum made headlines on November 4–5, 2025 with a stellar earnings report that ignited its stock. The firm announced Q1 FY2026 (quarter ended Sep 27, 2025) results featuring record-high sales of $533.8 million – about 58% higher than a year agosimplywall.st and even slightly above Wall Street’s consensus (FactSet had ~$526M)marketscreener.com. This top-line feat, the largest quarterly revenue in Lumentum’s 10-year historyoptics.org, was driven by unprecedented demand from AI and
5 November 2025
·····
Kratos Defense (KTOS) Soars 300% on Drone Boom – Is the Rally Sustainable?

Kratos Defense (KTOS) Soars 300% on Drone Boom – Is the Rally Sustainable?

1. Company Background and Overview of Kratos Defense & Security Solutions, Inc. Kratos Defense & Security Solutions, Inc. is a U.S. technology company serving the defense and national security market. Founded in 1994 and headquartered in San Diego, Kratos specializes in mission-critical systems for military and government agenciesinvesting.com. The company operates through two main segments – Kratos Government Solutions (KGS) and Unmanned Systems (US) – offering a wide array of products and services. These include satellite ground communication systems, jet-powered unmanned aerial vehicles (UAVs), missile and radar system solutions, advanced propulsion systems for missiles/spacecraft, cyber security and training platforms, and
5 November 2025
····
Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

(Each of these points is explored in detail below.) Company Overview Babcock & Wilcox Enterprises, Inc. (“B&W”) is an American energy technology and services provider with a 158-year legacy. Headquartered in Akron, Ohio, the company is historically renowned for its steam boilers used in power generation Wikipedia. Today, B&W’s offerings span advanced energy and environmental solutions for industrial and utility markets worldwide Tipranks. It engineers and supplies equipment for power generation (including waste-to-energy and fossil fuel plants), emissions control systems (like scrubbers and carbon capture), and related services/parts. B&W operates through three segments: Renewable, Environmental, and Thermal. The B&W Thermal
5 November 2025
·······
Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Market Performance and Recent Stock Price Trex stock has endured a steep slide in 2025, culminating in a dramatic plunge after its early November earnings announcement. On November 5, 2025, TREX opened around $34–35 per share – down roughly 26% from the prior day’s close Streetinsider. This selloff pushed the stock to fresh 52-week lows, shattering the previous low of ~$46 Finviz. Prior to the earnings drop, Trex had already been trending downward for months; with this latest collapse, shares have lost about 50% of their value year-to-date Finviz and over 50% from 12-month highs (which were near $80 Finviz).
5 November 2025
·····
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Company Overview: AI-Powered Biotech at the Intersection of Therapeutics & Biodefense Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotechainvest.comainvest.com. In practical terms, Lunai is developing both therapeutic platforms (for diseases like cancer and neurodegeneration) and advanced diagnostics/screening tools (including detecting chemical/biological threats), all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell (DC) therapy
5 November 2025
·····
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatmentreuters.com. On November 4, 2025, after market close, Biohaven announced that the FDA had issued a Complete Response Letter (CRL) rejecting the company’s New Drug Application. This CRL cited multiple concerns with Biohaven’s data: potential bias, design limitations, lack of pre-specification, and unmeasured confounding factors in the supporting studiesstocktwits.comstocktwits.com. In simpler terms, the FDA was uneasy with how Biohaven ran and analyzed its trials – particularly
5 November 2025
····
1 … 2,252 2,253 2,254 2,255 2,256 … 2,706

Stock Market Today

Nebius (NBIS) stock jumps 16% into weekend as AI trade whipsaws; earnings next week in focus

Nebius (NBIS) stock jumps 16% into weekend as AI trade whipsaws; earnings next week in focus

7 February 2026
Nebius shares jumped 16.6% to $86.10 on Friday, rebounding from a 10.3% drop Thursday. The company will report fourth-quarter and full-year 2025 results before the market opens on Feb. 12. U.S. jobs and inflation data are due next week after a delay from a government shutdown. Recent swings in Nebius stock followed volatility in AI-linked tech names after Alphabet’s spending update.
Go toTop